Archive for the ‘NASDAQ listed BVI Companies’ Category

Newly organized BVI company announced US$50 million public offering

Monday, June 19th, 2017

Bison Capital Acquisition (BCACU), a newly organized blank check company registered in the British Virgin Islands and headquartered in China, announced its plans to raise US$50 million in an initial public offering (IPO) on the week starting with June 19th. Bison Capital will issue 5,000,000 shares at the price of US$10.00 per share. Market capitalization of the company is US$53.8 million.

Bison Capital Acquisition was incorporated in the BVI as a business company with limited liability, and has the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, or engaging in other similar business combinations with one or more businesses. The company is planning to focus on businesses operating in Asia and North America, however it is not limited to particular industry or area. It was established in 2017 and has 3 employees.

Origin and Arcadia Biosciences entered into collaboration agreement

Wednesday, March 15th, 2017

Origin Agritech, LLC, a subsidiary of BVI-incorporated agricultural biotechnology company Origin Agritech Ltd., and Arcadia Biosciences, Inc., a California-based company focused on developing and commercializing agricultural productivity traits and products, announced their collaboration to achieve the export to the US of key corn biotechnology product developed in China, to complete global regulatory trials. The exported corn seed contains an insect resistance/herbicide tolerance trait discovered and developed in China.

The collaboration is a key milestone in BVI corporation’s strategic business plan of achieving global regulatory approvals for cultivation and international grain movement. This first-ever export of this kind strengthens Origin’s leading positions in China biotech market. Under the agreement signed between Origin and Arcadia, the US company will provide assistance to Origin in developing information for submission to regulatory authorities in the United States, China and other countries, to receive approval of their traits in corn. The project includes production of inbred and hybrid seed lines under quarantine conditions in Arcadia greenhouses.

Origin Agritech signed commercial agreement with DuPont Pioneer

Tuesday, January 10th, 2017

Agricultural biotechnology company Origin Agritech Ltd. signed a definitive agreement with DuPont Pioneer, which is the advanced seed and genetics business of DuPont (DD), providing high-quality seeds to farmers in more than 90 countries. Pursuant to this agreement, the BVI company will get access to non-GM corn seed products of DuPont Pioneer. It is expected that commercial seed products will be available for sale in the US market for spring 2017 planting.

This business agreement with DuPont followed the previous commercial agreement with the company signed in April 2016, to jointly develop new seed technologies in China for Chinese farmers. By words of Origin CEO Bill Niebur, the agreement with DuPont Pioneer is “a critical first step toward launching Origin’s North America strategic Pillar III, focused on serving the non-GM/Organic markets.”

Origin recently released advances in its Pillar I and II growth platforms. Today’s announcement supports progress in the launch of its Pillar III: North America non-GM/Organic growth platform.

Origin Agritech establishes North American office

Wednesday, October 5th, 2016

BVI-registered biotechnological company Origin Agritech Ltd., working in China, has started operations in North America, in Des Moines downtown, effective August 29, 2016. The establishment of the North America operations and international relations centre is a key step in a number of strategic actions to make Origin the leading global foundation biotech and seed development company.

Origin Agritech CEO Bill Niebur said in his comment that Des Moines “is an ideal location for Origin’s North American operations, providing superior access to talent, technologies and proximity to key target markets”. Company’s CEO, CFO and team members will be located at Des Moines, while main biotech and seed breeding operations, among them plant breeding and biotech research and development centre, will continue to be based in China. Company’s CTO will continue to oversee operations in China from Beijing. Presence of the company in North America is a result of its aim to focus on globalization and become a multinational corporation.